About
Remyelination program for multiple sclerosis
Areas of Focus
Categories
San Diego & Southern California
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
313
By Phase
PHASE2: 2PHASE1: 1
By Status
RECRUITING: 2COMPLETED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06869187Lead Sponsor
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
PHASE2Recruiting
35 participants
Started: Mar 28, 2025 · Completed: Mar 13, 2026
NCT06633016Lead Sponsor
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
PHASE2Recruiting
230 participants
Started: Sep 20, 2024 · Completed: Dec 31, 2025
NCT05528315Lead Sponsor
SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects
PHASE1Completed
48 participants
Started: Oct 12, 2022 · Completed: Sep 13, 2023
Funding History (1)
D
Aug 1, 2024
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...